- Home
- IGD vs IVA Comparison
IGD vs IVA Comparison
Compare IGD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGD
- IVA
- Stock Information
- Founded
- IGD N/A
- IVA 2011
- Country
- IGD United States
- IVA France
- Employees
- IGD N/A
- IVA N/A
- Industry
- IGD Trusts Except Educational Religious and Charitable
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- IGD Finance
- IVA Health Care
- Exchange
- IGD Nasdaq
- IVA Nasdaq
- Market Cap
- IGD 422.7M
- IVA 359.6M
- IPO Year
- IGD N/A
- IVA 2020
- Fundamental
- Price
- IGD $5.63
- IVA $3.58
- Analyst Decision
- IGD
- IVA Strong Buy
- Analyst Count
- IGD 0
- IVA 4
- Target Price
- IGD N/A
- IVA $10.50
- AVG Volume (30 Days)
- IGD 215.3K
- IVA 18.0K
- Earning Date
- IGD 01-01-0001
- IVA 03-26-2025
- Dividend Yield
- IGD 9.15%
- IVA N/A
- EPS Growth
- IGD N/A
- IVA N/A
- EPS
- IGD N/A
- IVA N/A
- Revenue
- IGD N/A
- IVA $14,591,573.00
- Revenue This Year
- IGD N/A
- IVA $15.38
- Revenue Next Year
- IGD N/A
- IVA $24.22
- P/E Ratio
- IGD N/A
- IVA N/A
- Revenue Growth
- IGD N/A
- IVA N/A
- 52 Week Low
- IGD $4.60
- IVA $1.53
- 52 Week High
- IGD $5.26
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- IGD 56.59
- IVA 54.47
- Support Level
- IGD $5.58
- IVA $3.48
- Resistance Level
- IGD $5.62
- IVA $3.77
- Average True Range (ATR)
- IGD 0.06
- IVA 0.22
- MACD
- IGD 0.01
- IVA -0.03
- Stochastic Oscillator
- IGD 89.13
- IVA 48.68
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.